Exubrion Therapeutics

What Exubrion Therapeutics does

Exubrion Therapeutics is a US-based private animal health company commercializing Synovetin OA, a veterinary radiotherapeutic device that delivers tin-117m (Sn-117m) conversion electron therapy as an intra-articular colloidal suspension to treat canine osteoarthritis. The product targets synovial inflammation at its source—deactivating macrophages and synoviocytes via localized, monoenergetic 127-158 keV emissions—providing up to one year of pain relief from a single injection, with greater than 99.1% of the radioisotope retained in the joint and no systemic side effects. Clinical data report 70-90% positive response rates, with 92% improvement in mild-to-moderate cases and 71% in severe cases, and preclinical rodent data published in Frontiers in Veterinary Science (2025) suggest disease-modifying potential beyond symptomatic relief.

The company distributes Synovetin OA exclusively through a B2B2C model: veterinarians must obtain state Radioactive Materials (RAM) licensing via Exubrion's RAM Navigator program, with support from F.X. Massé Associates, before purchasing the treatment and administering it to canine patients. A network of 100+ licensed US veterinary hospitals had been built by November 2025, augmented by consumer-facing marketing on ActiveDogNow.com that drives pet owners to request the treatment from their veterinarian. The company generates revenue primarily through per-treatment product sales to clinics (with pricing not publicly disclosed but covered by major pet insurance providers), supplemented by the enablement ecosystem (FastStart kits, RACE-approved CE, RAM licensing support) that functions as a recurring onboarding layer. A 2025 strategic collaboration with Vivos Inc. extends the tin-117m platform into oncology micro-injection applications, and exploratory usage in zoo and exotic animals signals future vertical expansion.

Exubrion is led by CEO Jennifer Kirk (appointed May 2025, ex-Medtronic and Occidental Petroleum), Executive Chair and interim-CEO predecessor Laurie McRay, Chief Operating Officer Nigel Stevenson (90+ publications, 30+ patents in radioisotope science), Chief Commercial Officer Eric Schreiber, and Chief Veterinary Officer Robert Menardi. The company is headquartered in Gainesville, Georgia with an additional office in Alpharetta, Georgia, and operates as a private corporation with no disclosed venture funding rounds.

Name

Exubrion Therapeutics

Legal name

Exubrion Therapeutics, Inc.

Website

https://synovetin.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

Exubrion Therapeutics is a US-based private animal health company that commercializes Synovetin OA, a tin-117m radiotherapeutic injection for canine osteoarthritis, distributing it through a network of 100+ licensed veterinary hospitals using a B2B2C model.

Ownership category

akta.pro rank

Product category

Veterinary Radiopharmaceuticals

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Biologics & Immunotherapies (Non-vaccine) (HLAMAEAK)

akta.pro secondary industry

Rehabilitation & Physical Therapy Devices (Laser, Hydrotherapy, TENS) (HLAMAFAK)

Keywords

• Veterinary radiopharmaceuticals
• Canine osteoarthritis treatment
• Radiosynoviorthesis therapy
• Companion animal health
• Veterinary medical devices

Headquarters

HQ city

Buford

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. Synovetin OA Treatment Product Sales: Exubrion generates revenue through the sale of Synovetin OA treatments to licensed veterinary hospitals and clinics. Veterinarians purchase the product and administer it to dogs in exchange for a treatment fee. The product is priced as a medical device/radiopharmaceutical and is covered by major pet insurance providers.
2. Licensing and Certification Fees: Veterinary practices must obtain radioactive materials (RAM) licensing through their state regulatory body, with Exubrion providing the RAM Navigator program to support the licensing process. This creates a barrier to entry and ensures only qualified facilities administer the treatment.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

Exubrion Therapeutics manufactures and distributes Synovetin OA, a sterile colloidal suspension of tin-117m microparticles administered as a single intra-articular injection to treat canine osteoarthritis. The radiotherapeutic device provides up to one full year of pain relief per treatment, targets synovial inflammation at its source, and is sold exclusively to licensed U.S. veterinary hospitals. Supporting offerings include the RAM Navigator licensing program, FastStart Kit for practices, and free RACE-approved continuing education for veterinarians.

Product overview

Exubrion Therapeutics offers a single core product: Synovetin OA, a radiotherapeutic veterinary device in a sterile colloidal suspension. The treatment leverages proprietary conversion electron therapy from tin-117m to target canine osteoarthritis inflammation at its source. A single outpatient injection provides up to 1 year of pain relief, with the active ingredient remaining in the body for only a few weeks while the therapeutic effect persists. The company provides supporting resources including a FastStart Kit for treatment centers, RAM Navigator licensing support, and free RACE-approved continuing education courses for veterinary professionals.

Differentiator

Problem solved

Functional benefit

Brands

• Synovetin OA: A groundbreaking radiotherapeutic treatment for canine osteoarthritis that provides up to 1 year of pain relief with a single injection using tin-117m technology.
• RAM Navigator
• ActiveDogNow

Products and services

• Synovetin OA Synovetin OA is a sterile colloidal suspension of tin-117m (Sn-117m) microparticles administered as a single intra-articular injection to treat canine osteoarthritis, particularly elbow OA. A single outpatient injection provides up to 1 full year of pain relief by targeting synovial inflammatory cells (macrophages and synoviocytes) while sparing surrounding tissues and producing no systemic side effects. It is sold exclusively to licensed U.S. veterinary hospitals and is covered by major pet insurance providers.

Quantifiable outcome

• 92% of dogs with mild to moderate osteoarthritis improved; 71% of dogs with more severe OA improved after Synovetin OA treatment
• +5 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Vivos Inc.coreStrategic or Co-development Partner · 29 October 2025Vivos Inc. and Exubrion Therapeutics have strengthened their strategic collaboration to develop targeted radioactive isotope technology for use in companion animals. Vivos is developing a Y-90 based brachytherapy device called RadioGel for treating non-resectable tumors in humans and animals. The partnership leverages complementary expertise—Vivos' oncology focus with Exubrion's tin-117m radiosynoviorthesis technology—to accelerate innovation in cancer and osteoarthritis treatments. Vivos' IsoPet division tests therapies on veterinary patients, and the companies are working on micro-injection systems for small tumors.
• F.X. Massé Associates, Inc.coreImplementation/ SI/ Consulting PartnerMedical physics consulting firm providing services related to radiation safety, shielding design, and regulatory compliance. Their extensive experience in medical and health physics fields supports the RAM Navigator program, helping veterinary practices obtain or amend Radioactive Materials licenses required to administer Synovetin OA. This partnership minimizes regulatory hurdles for veterinary practices.
• Cleveland Veterinary RehabilitationcoreChannel Partner/ Reseller/ DistributorSpecialized veterinary rehabilitation practice in Willoughby Hills, Ohio that was the first in Northeast Ohio to offer Synovetin OA. The practice offers a multimodal approach to pain management and rehabilitation, providing referrals and treatment for OA patients. They conduct weekly lunch-and-learn sessions and have developed consumer-focused brochures for referring veterinarians.
• VetcorcoreChannel Partner/ Reseller/ DistributorVetcor is a network of veterinary clinics. Murphy Road Animal Hospital in Dallas, part of the Vetcor network, became licensed to offer Synovetin OA in November 2025. This represents network-level distribution potential for Exubrion's treatment through a veterinary group purchasing/organizational structure.
• Animal ImagingminorChannel Partner/ Reseller/ DistributorVeterinary imaging center in Irving, Texas that offers in-house Synovetin OA treatments. Provides special pricing ($150 off per joint treated) and promotional treatment days. Demonstrates the treatment's adoption by specialty imaging practices.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Zoetis: Zoetis is the largest pure-play animal health company and directly competes with Synovetin OA through Librela (bedinvetmab), a once-monthly monoclonal antibody injection for canine OA pain. Both target the same veterinarian-prescriber channel and pet-owner end-customer for canine OA, but with fundamentally different mechanisms (mAb vs. radioisotope) and administration models.
• Elanco Animal Health: Elanco markets Galliprant (grapiprant), an NSAID specifically approved for canine OA pain and inflammation. Galliprant represents the most established daily oral competitor in the canine OA therapeutics market and competes for the same veterinarian prescription and pet-owner demand that Synovetin OA targets.
• VetStem Biopharma: VetStem Biopharma is a leading veterinary regenerative medicine company offering autologous stem cell therapy for canine OA and other orthopedic conditions. It directly competes in the canine OA treatment space with a disease-modifying biologic approach similar in positioning (though not mechanism) to Synovetin OA.
• Vivos Inc: Vivos Inc develops Y-90 based brachytherapy (RadioGel) and operates the IsoPet division delivering radioisotope therapies to animal patients. Vivos is both a strategic partner of Exubrion and a peer in the veterinary radioisotope therapy space, with overlapping scientific infrastructure and similar targeted-radiation approach for animal oncology indications.
• American Regent (Adequan): American Regent manufactures Adequan (polysulfated glycosaminoglycan), an injectable disease-modifying OA drug approved for both canine and equine use. Adequan competes in the same intra-articular injectable category and has established veterinarian relationships across US general practice.

Emerging players

• Ardent Animal Health: Ardent Animal Health provides regenerative and cell-based therapies for companion animals, including treatments for canine OA and orthopedic conditions. It competes in the disease-modifying veterinary OA space with a platelet and stem cell focus, primarily serving specialty and rehabilitation practices.
• Anivive Lifesciences: Anivive Lifesciences is a veterinary biotech company developing novel therapeutics for companion animals, including oncology and OA indications. It represents an emerging peer in the venture-backed veterinary drug/device development space targeting similar specialty practice channels as Exubrion.

Broad incumbents

• Boehringer Ingelheim Animal Health: Boehringer Ingelheim is one of the largest animal health companies globally, with a broad portfolio including NSAIDs (Metacam/meloxicam) and other pain management products for canine OA. It competes broadly in canine OA therapeutics with established distribution but not with a disease-modifying radioisotope mechanism.
• Vetoquinol: Vetoquinol is a global animal health company offering NSAIDs (e.g., robenacoxib/Onsior) and joint health products for companion animals. It competes broadly in canine OA pain management across veterinary channels, particularly in Europe and North America.
• Virbac: Virbac is a global animal health company with a broad portfolio spanning parasiticides, vaccines, and pain/inflammation products including options for canine OA. It represents a broad incumbent competitor in the veterinary OA therapeutic space with significant global distribution.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/exubrion-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exubrion Therapeutics